LRRK2 and Parkinson disease: Provided that PF-475 (and other kinase inhibitors) interact with mammalian (hLRRK2) or invertebrate (dLrrk2) kinase in a similar molecular mechanism, we anticipate that pharmacological inhibitors might effectively inhibit LRRK2 in PD patients [59, 60].